tirilazad suppliers

Suppliers by country/region

• United States(2)
• South Korea(1)

Company Type

• Trader

Properties

Safety Information

Use

Tirilazad mesylate, a novel 21 -aminosteroid derivative, has been marketed in Austria for the intravenous treatment of subarachnoid hemorrhage (SAH) in male patients. Studies have indicated involvement of lipid peroxidation and/or lipid hydrolysis in the genesis of SAH-initiated microvascular damage and prolonged vasospasm of the large cerebral vessels. Tirilazad mesylate is a highly lipophilic compound that localizes to the cell membrane. It is a potent inhibitor of lipid peroxidation induced by oxygen free radicals, purely through a mechanism similar to vitamin E by scavenging lipid peroxyl radicals, and is a stabilizer of biological membranes. Tirilazad mesylate has been demonstrated to have a positive effect in reducing symptomatic vasospasm, cerebral infarction, and neurological dysfunction. Clinically, it is reportedly effective in reducing mortality in male SAH patients relative to the control group. The title compound is also reportedly in clinical trials for ischemic stroke, spinal cord injury, and for non-systemic ocular applications. Little or no behavioral and physiological side effects have been reported.